Skip to main content
AstraZeneca PLC logo

AstraZeneca PLC — Investor Relations & Filings

Ticker · AZN ISIN · GB0009895292 LEI · PY6ZZQWO2IZFZC3IOL08 IL Manufacturing
Open in API
Filings indexed 3,397 across all filing types
Latest filing 2020-05-11 Foreign Filer Report
Country GB United Kingdom
Listing IL AZN

About AstraZeneca PLC

https://www.astrazeneca.com/

AstraZeneca PLC is a global, science-led biopharmaceutical company that focuses on the discovery, development, and commercialization of prescription medicines. The company's portfolio is concentrated on several main therapy areas, including Oncology; Cardiovascular, Renal & Metabolism; and Respiratory & Immunology. AstraZeneca is committed to advancing healthcare through a robust research and development pipeline, aiming to deliver innovative medicines that address significant unmet medical needs for millions of patients worldwide. The company leverages scientific innovation to transform the future of healthcare and improve patient outcomes.

Recent filings

Filing Released Lang Actions
ASTRAZENECA RECOVERY OF GLOBAL RIGHTS TO BRAZIKUMAB (MEDI2070) FROM ALLERGAN COM
Foreign Filer Report
2020-05-11 English
LYNPARZA APPROVED IN THE US AS 1ST-LINE MAINTENANCE TREATMENT WITH BEVACIZUMAB F
Foreign Filer Report
2020-05-11 English
Enhertu designated gastric cancer BTD
Regulatory Filings Classification · 98% confidence The document is a press release issued via the Regulatory News Service (RNS) of the London Stock Exchange. It announces that AstraZeneca's drug 'Enhertu' has been granted Breakthrough Therapy Designation by the FDA. While it contains detailed information about the drug and clinical trials, it is fundamentally a corporate announcement regarding regulatory news, which falls under the 'RNS' category for general regulatory announcements.
2020-05-11 English
Brazikumab rights recovered by AstraZeneca
Regulatory Filings Classification · 98% confidence The document is an RNS (Regulatory News Service) announcement from AstraZeneca regarding the completion of a business agreement to recover global rights to a drug (brazikumab) from Allergan. It details the financial and operational implications of this transaction. Since it is a specific corporate announcement regarding a business development/transaction that does not fit into the more specific categories like M&A (which usually implies a full company takeover) or other specialized categories, it is best classified as a general Regulatory Filing (RNS).
2020-05-11 English
Lynparza gets broader US ovarian cancer approval
Regulatory Filings Classification · 98% confidence The document begins with 'RNS Number : 4496M' and is dated May 11, 2020. It announces a significant regulatory event: the FDA approval of Lynparza in combination with bevacizumab for a specific cancer indication. The content is a press release detailing clinical trial results (PAOLA-1) and financial considerations related to the approval. This format—a formal announcement of a material event released via the London Stock Exchange's RNS system—is characteristic of a general regulatory announcement that doesn't fit into the more specific categories like 10-K, ER, or DIV. Since it is a formal, material announcement distributed through the RNS system, the most appropriate classification is Regulatory Filings (RNS), as it serves as the general regulatory announcement category.
2020-05-11 English
FARXIGA APPROVED IN THE US FOR THE TREATMENT OF HEART FAILURE IN PATIENTS WITH H
Foreign Filer Report
2020-05-06 English

Browse filings by year

34 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.